drugset / Trial / NCT07107750
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
Based on preclinical data from the Lim lab (WUSM), the investigators hypothesize that IRAK4 inhibition cripples tumor-intrinsic survival signaling and effectively overcomes the desmoplastic and immune-suppressive tumor microenvironment (TME) to render chemo- and immunotherapies effective in GI malignancy. Therefore, this trial is designed to evaluate the combination of emavusertib (CA-4948) and standard chemoimmunotherapy in untreated advanced or metastatic biliary tract cancer (BTC).
Timeline
- Start
- 2026-03-27
- Primary completion
- 2030-06-30
- Completion
- 2032-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emavusertib | Small molecule | — | Oral |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Durvalumab | Monoclonal antibody | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | Intravenous |